



PPD Recognized for Expertise in Clinical Research

Honored as Clinical Team of the Year at PharmaTimes' ceremony in London

WILMINGTON, N.C., (February 20, 2012) - Demonstrating its expertise in [clinical research](#), Pharmaceutical Product Development, LLC (PPD) today announced that *PharmaTimes* magazine has named a team of PPD researchers the 2012 Clinical Team of the Year.

The honor, bestowed at the Clinical Researcher of the Year Awards in London on February 16, capped a demanding, seven-hour competition in which six teams of researchers raced a time clock while tackling a series of challenging drug-development scenarios, then presented their creative solutions.

"To win the *PharmaTimes* Clinical Team of the Year Award requires outstanding technical competence and the ability to work under pressure whilst still maintaining superb team dynamics," said Sean Morgan-Jones, director, *PharmaTimes*. "PPD's achievement in securing the win should give them great confidence in their abilities as a first-rate clinical research team."

PPD's experienced clinical research associates (CRAs) monitor clinical trials to ensure compliance with clinical trial protocols, standard operating procedures and guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and guidelines for Good Clinical Practice (ICH/GCP).

"PPD's clinical research professionals embody our company's expertise, commitment and passion for delivering excellence in our clients' important research programs," said Roger Newberry, PPD vice president of clinical management for Europe, the Middle East and Africa. "We congratulate our colleagues on their achievement and are pleased that PPD's leadership in clinical research continues to be recognized by our industry peers."

The competition was created in 1999 to provide pharmaceutical companies, clinical research organizations and research sites of the United Kingdom's National Health Service (NHS) an opportunity to test their professional skills in a program of competency-based exercises developed through cross-industry collaboration.

Some 270 clinical researchers and 41 NHS research sites entered the competition in February 2011. They were filtered through a number of exercises to identify the top individuals, teams and organizations, which were invited to the finals in November 2011 to face the judges.

About PPD

PPD is a leading global [contract research organization](#) providing [drug discovery](#), development and lifecycle management services. Our clients and partners include [pharmaceutical](#), [biotechnology](#), [medical device](#), academic and [government](#) organizations. With offices in 45 countries and more than 11,500 professionals worldwide, PPD applies innovative technologies, [therapeutic expertise](#) and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppd.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the Clinical Researcher of the Year recognition, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: competition in the outsourcing industry; the ability to attract, integrate and retain key personnel, including a new CEO; risks associated with and dependence on strategic relationships; rapid technological advances that make our services less competitive; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD's ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with acquisitions and investments; compliance with drug development regulations; changes in the regulation of the drug development process; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.

Contacts

Media:

Ned Glascock

+1 910 558 8760

ned.glascock@ppdi.com

Investors:

Luke Heagle

+1 910 558 7585

luke.heagle@ppdi.com